Please use this identifier to cite or link to this item: https://doi.org/10.3390/ijms20133272
Title: Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers
Authors: CHONG SUET YEN 
LEE CHOON KEONG 
Huang, Chenyuan
Ou, Yi Hsuan
CHARLES, CHRISTOPHER JOHN 
ARTHUR MARK RICHARDS 
Neupane, Yub Raj
Pavon, Maria Vazquez
ZHARKOVA, OLGA 
Pastorin,Giorgia 
WANG JIONGWEI 
Keywords: Science & Technology
Life Sciences & Biomedicine
Physical Sciences
Biochemistry & Molecular Biology
Chemistry, Multidisciplinary
Chemistry
extracellular vesicles
cardiovascular disease
biomarker
therapeutic
drug delivery
theranostics
CELL-DERIVED EXOSOMES
PLURIPOTENT STEM-CELLS
CARDIOMYOCYTE APOPTOSIS
ISCHEMIA-REPERFUSION
CARDIAC REGENERATION
INDUCE ANGIOGENESIS
ENDOTHELIAL-CELLS
TARGETED DELIVERY
ADIPOSE-TISSUE
PROTEIN-LEVELS
Issue Date: 1-Jul-2019
Publisher: MDPI
Citation: CHONG SUET YEN, LEE CHOON KEONG, Huang, Chenyuan, Ou, Yi Hsuan, CHARLES, CHRISTOPHER JOHN, ARTHUR MARK RICHARDS, Neupane, Yub Raj, Pavon, Maria Vazquez, ZHARKOVA, OLGA, Pastorin,Giorgia, WANG JIONGWEI (2019-07-01). Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20 (13). ScholarBank@NUS Repository. https://doi.org/10.3390/ijms20133272
Abstract: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. T. Cardiovascular diseases (CVD) represent the leading cause of morbidity and mortality globally. The emerging role of extracellular vesicles (EVs) in intercellular communication has stimulated renewed interest in exploring the potential application of EVs as tools for diagnosis, prognosis, and therapy in CVD. The ubiquitous nature of EVs in biological fluids presents a technological advantage compared to current diagnostic tools by virtue of their notable stability. EV contents, such as proteins and microRNAs, represent specific signatures of cellular activation or injury. This feature positions EVs as an alternative source of biomarkers. Furthermore, their intrinsic activity and immunomodulatory properties offer EVs unique opportunities to act as therapeutic agents per se or to serve as drug delivery carriers by acting as miniaturized vehicles incorporating bioactive molecules. In this article, we aim to review the recent advances and applications of EV-based biomarkers and therapeutics. In addition, the potential of EVs as a drug delivery and theranostic platform for CVD will also be discussed.
Source Title: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
URI: https://scholarbank.nus.edu.sg/handle/10635/159426
ISSN: 1422-0067
DOI: 10.3390/ijms20133272
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Extracellular Vesicles in Cardiovascular Diseases Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carri.pdf1.08 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

45
checked on Dec 6, 2021

WEB OF SCIENCETM
Citations

32
checked on Oct 4, 2021

Page view(s)

268
checked on Dec 2, 2021

Download(s)

3
checked on Dec 2, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.